Inactive Instrument

News Chromadex Corp OTC Bulletin Board

Equities

CDXC

US1710771007

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Apr. 09	Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating	MT
Mar. 11	HC Wainwright Adjusts Price Target on ChromaDex to $6 From $5, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating	Apr. 09	MT
ChromaDex Announces Tru Niagen is Now Third-Party Verified through the Alkemist Assured Transparency Program	Mar. 27	AQ
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program	Mar. 26	BU
ChromaDex : March 2024 Investor Presentation	Mar. 18	PU
HC Wainwright Adjusts Price Target on ChromaDex to $6 From $5, Maintains Buy Rating	Mar. 11	MT
Transcript : ChromaDex Corporation, Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results	Mar. 06	BU
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q4 Revenue $21.2M, vs. Street Est of $20.7M	Mar. 06	MT
ChromaDex Corporation Provides Earnings Guidance for 2024	Mar. 06	CI
ChromaDex Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
ChromaDex Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024	Feb. 21	BU
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024	Feb. 06	AQ
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024	Feb. 05	BU
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference	Jan. 26	BU
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen	Dec. 21	AQ
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®	Dec. 20	BU
ChromaDex Corporation, Chromadex, Inc. and ChromaDex Analytics, Inc Enter into an Amendment to the Business Financing Agreement Dated November 1, 2019 Among the Borrowers and Western Alliance Bank	Dec. 13	CI
Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+	Dec. 12	CI
ChromaDex Says High-Dose Niagen Safe for Parkinson's Disease Patients in Phase 1 Study	Nov. 30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Chromadex Corp OTC Bulletin Board

Equities

CDXC

US1710771007

Summary

Filters